Drug Trial Radar · NCT01134120
A Study in Myeloproliferative Disorders
Last checked: Nov 19, 2026Latest source record: Apr 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Planned (sponsor's estimate)
Start
Apr 2010
Primary completion
Apr 2014
Study completion Feb 22, 2018
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 31, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.
Conditions
- Myeloproliferative Disorders
- Thrombocythemia, Essential
- Polycythemia Vera
- Primary Myelofibrosis
Interventions
LY2784544Drug
LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of a recommended Phase 2 dosing regimenTime frame: Time of first dose until last dose
- Number of participants with clinical significant effectsTime frame: Time of first dose until last dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Houston, Texas
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.